How it works and why it could help with exercise challenges. Plus, how diaTribe readers can try it for free

Third diabetes partnership for Fitbit, focused on integrating activity and sleep data with diabetes data on the phone and watch

How I avoid highs, prevent lows, and stop blood sugar frustration during exercise

Health Canada has approved the once-daily insulin for adults with type 1 and type 2 diabetes

Ease, comfort, and actionable patterns, but some challenges with insurance coverage

Device Updates from Abbott, Dexcom, Insulet, Medtronic, and Tandem

Get weekly email and phone notifications summarizing time-in-range and glucose trends from the updated Dexcom Clarity app

Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba

How do I talk to family and friends about diabetes? Is this MY burden to bear? Are loved ones a “diabetes bright spot” or “diabetes police”?

Dexcom CGM for Medicare shipments start with hopefully more to come, Ascencia Contour Next One meter added, and why remote monitoring is not enabled

Lilly announces new program, in partnership with Express Scripts, to provide insulin directly to people with diabetes and high out of pocket drug expenses

First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company

Information about diabetes supplies for those hit by the storms and for those who can help them

How do I stay in range while sleeping?

Research presented at ADA’s 2017 conference shows exciting advances in a host of diabetes drugs – including heart benefits, improved glucose control, lower cholesterol,...

FDA approves Lucentis for all types of diabetic retinopathy and IBM announces a new technology that helps doctors better diagnose retinopathy

Initiative encourages pump and CGM devices to use “open protocols” to enable the DIY community, innovation, and more options for automated insulin delivery

A new basal insulin is on the horizon in the US with Merck’s LUSDUNA Nexvue, but launch timing obscured by ongoing lawsuit

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins

Jim Hirsch, diaTribe contributor and bestselling author, weighs in on a damaging diabetes myth